Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long‐acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double‐blind, placebo‐controlled phase Ia and Ib/II studies

Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long‐acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double‐blind, placebo‐controlled phase Ia and Ib/II studies

Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low‐density lipoprotein‐cholesterol (LDL‐C) by decreasing the expression of the LDL‐receptor on hepatic cells. Ongericimab (JS002) is a novel PCSK9 monoclonal antibody that exhibits a long‐acting LDL‐C lowering effect by...

Full description

Saved in:
Bibliographic Details
Main Authors: Juanjuan Jiang, Li Xu, Lin Chai, Xiaoyuan Guan, Li Zhang, Hong Liu, Yan Yan, Lili Li, Yi Zhao, Xuelian Bai, Lei Tian, Youhong Jia
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.70061
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/cts.70061

Similar Items